This year, there was a surge of new lung cancer treatments, more options for patients with earlier-stage disease, and growing ...

The committee recommended the combo for patients with EGFR exon 19 deletions or exon 21 L858R substitution mutations based on data from the MARIPOSA trial.

The company said the combo could help overcome resistance to EGFR inhibitors in patients whose tumors harbor the mutation.

The firm is submitting data showing that a one-time treatment with ST-920 led to a positive annualized estimated glomerular filtration rate slope.

The Recommended Uniform Screening Panel now includes DMD and MLD, which has implications for firms developing treatments for ...

While autologous therapies are mainstream in blood cancers, experts warn against overhyping allogeneic and in vivo approaches ...

The firm's Phase I/II study yielded responses in mCRPC patients with androgen receptor mutations but it wasn't as promising in HR-positive breast cancer.

The FDA converted the PARP inhibitor's 2020 accelerated approval to full approved based on results from the Phase III TRITON3 trial.

The UC Berkeley spin-out aims to develop one-time treatments for chronic and rare diseases using an RNA- and LNP-based platform.

Findings from two clinical trials suggest Novartis' Itvisma is safe and effective for SMA patients over two years old.

The grant will fund preclinical studies of the dCK inhibitor TRE-515 with KRAS inhibitors in mice, which will then inform the design of clinical trials.

Experts at SABCS said better prospective trials of ctDNA and more sensitive assays could bring ctDNA testing in breast cancer ...